

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Beta Carotene
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Avivagen Accelerates Plans for Commercial Launch of Its OxC-Beta™ Technology
Details : OxC-beta has been shown to have a multi-fold increase in the expression of the IFNGR1/CD119, TLR2, TLR4, CD14, and LY96/MD2 genes involved in pathogen defence.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Beta Carotene
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Beta Carotene
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Newcastle University | Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of SNPs in the BCMO1 Enzyme
Details : Beta-Carotene is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Vitamin A Deficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2014
Lead Product(s) : Beta Carotene
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Newcastle University | Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
